Table 2.
Results of Cox regression analysis for failure-free survival.
| Variables (Reference) | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age ≥ 65 years (<65 years) | 1.78 (0.82–3.87) | 0.145 | 1.33 (0.55–3.24) | 0.529 |
| Obesity (non-obesity) | 0.42 (0.19–0.93) | 0.033 | 2.51 (0.60–10.49) | 0.207 |
| Sarcopenia (no sarcopenia) | 6.18 (1.87–20.44) | 0.003 | 6.69 (1.57–28.49) | 0.010 |
| SFI ≥ median (<median) | 0.34 (0.16–0.75) | 0.007 | 0.30 (0.08–1.07) | 0.063 |
| VFI ≥ median (<median) | 1.04 (0.51–2.15) | 0.912 | ||
| VSR ≥ median (<median) | 1.42 (0.69–2.93) | 0.342 | ||
| PSA ≥ median (<median) | 1.17 (0.56–2.41) | 0.677 | 0.91 (0.36–2.30) | 0.843 |
| Abiraterone acetate (docetaxel) | 0.88 (0.37–2.08) | 0.774 | ||
| ECOG PS ≥ 1 (0) | 2.39 (1.12–5.14) | 0.025 | 2.10 (0.93–4.72) | 0.073 |
| Gleason score ≥ 8 (<8) | N/A | 0.955 | ||
| Stage cT4 (≤cT3) | 0.82 (0.38–1.77) | 0.618 | ||
| Regional LN metastasis (no) | 1.47 (0.56–3.85) | 0.431 | ||
| Bone metastasis (no) | 1.27 (0.48–3.31) | 0.632 | ||
| Visceral metastasis (no) | 1.13 (0.51–2.46) | 0.768 | ||
| High-volume (low-volume) | 2.43 (0.84–7.04) | 0.102 | 1.41 (0.24–8.33) | 0.704 |
| High-risk (low-risk) | 2.95 (0.89–9.78) | 0.078 | 0.911 (0.36–2.30) | 0.843 |
Variables with p < 0.10 in the univariable analysis are entered into the multivariable analysis, with age, baseline PSA level, disease volume, and disease risk being fixed.